Can AMH help with menopause?

Anti-Müllerian hormone (AMH) is a well-studied biomarker of ovarian reserve, reflecting the remaining egg pool. Observational studies indicate that lower AMH levels are associated with earlier menopause onset. However, AMH is not a diagnostic test for menopause itself; it provides a probabilistic estimate of timing. The evidence is human-moderate, based on cohort and cross-sectional studies, not randomized trials. Individual AMH levels vary widely due to age, genetics, lifestyle, and hormonal factors, limiting predictive precision. Clinically, AMH is primarily used in fertility assessment, not for menopause diagnosis. For determining menopausal status, established methods like FSH, estradiol, and menstrual history are more reliable. The provided context (MyBody-X DNA tests for CYP2D6, CYP2C19, ALDH2, etc.) does not include AMH or menopause-related data. Therefore, no direct evidence from this context supports the use of AMH for menopause management. Caveat: AMH testing should not replace clinical evaluation; always consult a healthcare provider for menopause-related concerns.